A practical approach for the synthesis of lactate dehydrogenase A inhibitor GNE-140 DOI
Jian Zhou, Jiaqi Liang, Qijie Gong

et al.

Tetrahedron Letters, Journal Year: 2024, Volume and Issue: 154, P. 155395 - 155395

Published: Dec. 1, 2024

Language: Английский

Lactoferrin conjugated radicicol nanoparticles enhanced drug delivery and cytotoxicity in prostate cancer cells DOI

Zeinab Kooshan,

Srilakshmi Srinivasan, Taskeen Iqbal Janjua

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177300 - 177300

Published: Jan. 1, 2025

Language: Английский

Citations

3
Regulation of newly identified lysine lactylation in cancer DOI
Xin Gao,

Chaoyu Pang,

Zhiyao Fan

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 587, P. 216680 - 216680

Published: Feb. 10, 2024

Language: Английский

Citations

15
Machine Learning-based Lactate-Related Genes Signature Predicts Clinical Outcomes and Unveils Novel Therapeutic Targets in Esophageal Squamous Cell Carcinoma DOI

Chuting Yu,

Yan Bian, Ye Gao

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217458 - 217458

Published: Jan. 1, 2025

Language: Английский

Citations

1
Lactoferrin-Encapsulated Dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer DOI

Sugarniya Subramaniam,

Varinder Jeet, Jennifer H. Gunter

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217522 - 217522

Published: Feb. 1, 2025

Language: Английский

Citations

1
From Pathogenesis to Precision Medicine: Transformative Advances in Research and Treatment of Ameloblastoma DOI Creative Commons
Zhao Zhang, Gan Xiong, Cheng Wang

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217448 - 217448

Published: Jan. 1, 2025

Language: Английский

Citations

0
Interrogation of the Tumor Microenvironment by Nanoparticles DOI
Prasanta Panja,

Upender Manne,

Vibhudutta Awasthy

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217454 - 217454

Published: Jan. 1, 2025

Language: Английский

Citations

0
HVEM as a Tumor-Intrinsic Regulator in Non-Small Cell Lung Cancer: Suppression of Metastasis via Glycolysis Inhibition and Modulation of Macrophage Polarization DOI Creative Commons
Yuanshan Yao, Bin Li, Chunji Chen

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107604 - 107604

Published: Jan. 1, 2025

Language: Английский

Citations

0
Intranuclear TCA and mitochondrial overload: the nascent sprout of tumors metabolism DOI

Weixi Yuan,

Guozhong Lu, Yin Zhao

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217527 - 217527

Published: Feb. 1, 2025

Language: Английский

Citations

0
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway DOI Creative Commons
Wang Bei, Zixuan Wang,

Zhizhen Zhou

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 26, 2025

Metabolic reprogramming plays a pivotal role in the development and progression of tumors. Tumor cells rely on glycolysis as their primary energy production pathway effectively utilize biomolecules generated by pentose phosphate (PPP) for efficient biosynthesis. However, 6-phosphogluconate dehydrogenase (6PGD), crucial enzyme PPP, remains unexplored esophageal squamous cell carcinoma (ESCC). In this study, we observed significant upregulation 6PGD expression ESCC tissues, which correlated with an unfavorable prognosis among patients. The experiments demonstrated that knockdown induces oxidative stress suppresses proliferation. Mechanistically, is achieved through AMPK activation subsequent inhibition downstream mTOR phosphorylation. Moreover, physcion has been found to inhibit activity exert its anti-ESCC effect via AMPK/mTOR pathway. Subsequently, conducted both vitro vivo validate anticancer efficacy combining metformin, activator, physcion. results significantly enhanced growth. This study elucidates impact proliferation along underlying molecular mechanisms, highlighting potential therapeutic target ESCC. Furthermore, investigated novel approach improved anti-tumor therapy involving metformin. These findings will contribute new insights clinical treatment strategies while providing theoretical foundation developing targeted therapies.

Language: Английский

Citations

0
Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation DOI
Wenying Shan, Shaolin Zhang, Yehuda G. Assaraf

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: unknown, P. 167859 - 167859

Published: April 1, 2025

Language: Английский

Citations

0